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Objective: The NordiNet® International Outcome Study (IOS), a large-scale, non-interventional, multi-centre,
real-world study of Norditropin® treatment, registers insulin-like growth factor-I (IGF-I) values, as measured
by different assays. This paper considers the potential biases introduced by using a single IGF-I reference data
set in analysing NordiNet® IOS data.
Design: To evaluate possible biases from different IGF-I assays used across NordiNet® IOS, a mixed-effect linear
model was ﬁtted to IGF-I data (analyses on log-transformed data). Pre-growth hormone treatment (pre-GHT)
IGF-I values were assumed to depend on diagnosis, sex and age. During GHT, a treatment-effect dependent on
these factors was added. Differences between assays were assumed multiplicative on the original scale. Individ-
ual measurements were scaled to a common level (Nichols Advantage) giving adjusted IGF-I standard deviation
score (SDS) values.
Results: In total, 49 495 IGF-I measurements were available from 9481 paediatric patients. Mixed-effect linear
modelling showed a systematic difference between IGF-I levels measured by different assays. Differences were
minimised when assessing change in IGF-I SDS from the start of GHT to 1-year follow-up. This applied to values
adjusted for actual-assay used and for unadjusted delta IGF-I SDS values. Largest differences between unadjusted
change in IGF-I SDS values were: for growth hormone deﬁciency 0.1 (girls) and 0.3 (boys); for small-for-
gestational age 0.1; and for Turner syndrome 0.2. Similar magnitude differences were seen for data with un-
known assay.
Conclusions: Analysis and modelling suggest the current approach to IGF-I data collection and analyses in the
NordiNet® IOS is sound: in a large cohort without assay-used information, potential bias is minimised by
analysing changes in IGF-I SDS.© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Themeasurement of circulating insulin-like growth factor I (IGF-I) by
sensitive immunoassays is widely established in the diagnosis of growth-T, growth hormone treatment;
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. This is an open access article underhormone (GH) related disorders and is crucial in the assessment and
monitoring of GH replacement therapy [1–4].
Due to heterogeneity in assay characteristics, there can be consid-
erable differences between the results provided by currently avail-
able IGF-I assays [4,5]. For IGF-I assays, differences in the choice of
standard and its handling and calibration within a given assay affect
the comparability of assays [6]. To improve standardisation, in 2009
the Expert Committee on Biological Standardization of the World
Health Organization formally adopted the preparation of the ﬁrst In-
ternational Standard for IGF-I as the universal calibrant for immuno-
assays. These standards are recommended in laboratory practice [1].
However, it should be noted that not all manufacturers currently
adopt the standard.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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tions is recognised as imperative for the study of IGF-I data from speciﬁc
patient populations [2,7]. For children and adolescents, such normative
data should be age-adjusted [3] to accurately reﬂect the age intervals
and Tanner stages during which there are rapidly changing IGF-I con-
centrations [5].
One of the largest studies undertaken to establish method-speciﬁc
reference IGF-I ranges used the Nichols Advantage® assay, which was
considered the gold standard until its withdrawal in 2006 [2]. Norma-
tive data also exist for an automated assay system currently in use, the
Immulite system [8] but, in general, reference data are poor for many
of the other assays on themarket [6]. In recent years there have been at-
tempts to better deﬁne normative reference values for IGF-I as, for ex-
ample, in a recent congress report based on a study of the automated
IDS-iSYS IGF-I assay that constructed IGF-I reference ranges using the
LMS (lambda-mu-sigma) method [9] (see Supplementary pages for a
description and discussion of the calculation of reference values and
the LMS method).
The NordiNet® International Outcome Study (IOS) (NCT00960128)
is a large-scale, non-interventional, multi-centre study that aims to
gather long-term data on the safety and effectiveness of Norditropin®
treatment in the usual clinical setting [10–12]. A major goal is to deter-
mine the predictive value, if any, of pre-treatment factors such as IGF-I
levels on outcome. The study also aims to evaluate the effect of
Norditropin® treatment on IGF-I as a key marker of GH activity. Due
to the growth-promoting effects of IGF-I, causality is also being
studied.
Large observational studies like NordiNet® IOS can offer a unique
opportunity to evaluate how IGF-I levels and patterns associate with
the effectiveness and safety of GH replacement therapy. However, inter-
pretation of data from such a real-world study must take account of
both the biases inherent in IGF-I assays and the limitations imposed
on data interpretation by aspects of the study protocol. The protocol
for NordiNet® IOS provides clear guidance concerning the data to be
captured; however, data collection is ultimately conducted in accor-
dance with normal clinical practice. This means that a blood sample is
not required at each patient visit, and IGF-I measurements only become
available upon thediscretion of the treatingphysicians in their everyday
clinical practice. Furthermore, in NordiNet® IOS, IGF-I levels are mea-
sured using different assays depending on the differing clinical and lab-
oratory practices in the real-world setting. Assay information may be
available, but this is not mandatory information in NordiNet® IOS.
IGF-I measurements are, therefore, reported from multiple sources
and locations, and the data reﬂect inter-assay aswell as intra-assay var-
iability. No information about individual assay performance and quality
is available. While some clinics and laboratories probably use the same
assay method, since the start of the registry and during the NordiNet®
IOS study period, several different assays have become available, adding
to the possibility of inter-assay variability within clinics, and even with-
in patients over time.
The current approach for evaluation of NordiNet® IOS IGF-I data has
been to use a reference data set [2] based on themost frequently report-
ed assay within NordiNet® IOS to date, which has historically been the
Nichols Advantage. However, this approach leads to an inevitable bias,
since a precise standard deviation score (SDS) calculation for IGF-I mea-
surements assessed with other assays is not possible.
This paper aims to assess IGF-I data from NordiNet® IOS, and specif-
ically seeks to evaluate and discuss the potential biases introduced by
using a single reference data set that is suboptimal for measurements
made by other assays. The model and methods applied in this paper
aim to assess and show that despite study limitations, historic differ-
ences in choice and use of assay methods, and limited assay informa-
tion, there are useful IGF-I data and data trends to report from the
NordiNet® IOS database. The paper does not aim to suggest methods
for use in clinical practice, but rather to evaluate a proposed strategy
for drawing scientiﬁc and clinically meaningful conclusions utilisingdata from the heterogeneous populations and practices reported in ob-
servational studies.
2. Methods
2.1. Study design
The study design of the on-going NordiNet® IOS, launched in 2006,
is described in detail elsewhere [10]. In brief, 19 countries are participat-
ing in NordiNet® IOS and those eligible for inclusion are paediatric and
adult patients who are already on, or starting, Norditropin® treatment
upon the discretion of the treating physicians [10].
The study population considered in this analysis of NordiNet® IOS
comprised paediatric patients with a diagnosis of growth hormone
deﬁciency (GHD), patients born small-for-gestational age (SGA) and
patients with Turner syndrome (TS) receiving growth hormone-
replacement therapy with Norditropin®.
The study database uses an electronic, web-based platform
(NordiNet®) for electronic data capturing in study case report forms
(CRFs), which provide automatic data validation at data entry. All
anonymised patient data reported into the central database are man-
aged by the Novo Nordisk Epidemiology Department in Denmark.
2.2. Data extraction
Key demographic and clinical characteristics (captured as described
in the NordiNet® IOS study design [10]) reported here include the base-
line characteristics of patient age, sex and clinical diagnosis, and data re-
lating to GH treatment (GHT). In order to evaluate and discuss the
potential biases introduced by using a single reference data set for
IGF-I SDS calculation, all valid IGF-I measures available from paediatric
patients diagnosed with GHD, SGA or TS from 2003 to 2012 in the
NordiNet® IOS were extracted from the central database. Where avail-
able, information on the assay type/fabricant was extracted.
2.3. Reference data
According to reported assay information in NordiNet® IOS, Nichols
Advantage has been the most commonly used assay to date, which
spans the time from the start of NordiNet® IOS to the present day,
and thus reﬂects retrospective trends in assay choice and use. Addition-
ally, since the Brabant reference data are based on one of the largest
published studies to date in relevant normative cohorts [2], these refer-
ence data have been used for the calculation of IGF-I SDS values in all
previous analyses of IGF-I data from NordiNet® IOS. Local laboratory
reference intervals have not been used given the difﬁculties of deﬁning
‘normal’ levels from local data.
2.4. Statistical analysis, test models and validation of models
The objectives of the statistical analysis were: (1) to evaluate possi-
ble biases due to different IGF-I assays; (2) to evaluate possible biases
due to different IGF-I reference data; and (3) to evaluate the representa-
tiveness of the sample used for the assay evaluation. For all three objec-
tives, both absolute values and relative changes in IGF-I SDS were
included in the evaluation.
In order to evaluate possible biases due to different assays, the differ-
ences between the assays used across NordiNet® IOS were estimated,
based on IGF-I data with available assay information. This was done by
ﬁtting a mixed-effect linear model to the repeated IGF-I measurements.
The mixed-effect model was chosen as it gives correct estimates of
treatment and other ﬁxed effects in the presence of correlated errors
among random effects. Additionally the mixed-effect model handles
missing values [13] (see Supplementary pages for a more detailed de-
scription of the model and the model formula). For each patient, all
measurements taken before the ﬁrst GH dose were deﬁned as the
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Fig. 1.Mean IGF-I levels by age group, sex and indication. (See also Supplementary Fig. 2
for values, per indication, showing age group and sex, with 95% conﬁdence intervals.)
GHD, growth hormone deﬁciency; SGA, small-for-gestational age.
Table 1
Multiplicity adjustment factors with 95% conﬁdence interval (CI) by IGF-I assay and GH
dose.
Multiplicity factor Lower 95% CI Upper 95% CI
IGF-I assay
Biochem RIA 0.86 0.80 0.93
DSL 1.18 1.13 1.24
Immulite 1.17 1.08 1.27
Immundiagnostik 0.83 0.76 0.90
Immunotech 1.34 1.28 1.40
Mediagnost 0.91 0.86 0.96
Nichols Advantage 1.00
GH dose (μg/kg/day)
0 1.00
10 1.03 1.02 1.05
20 1.06 1.03 1.09
30 1.10 1.05 1.14
40 1.13 1.07 1.19
50 1.16 1.08 1.25
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the ﬁrst GH dose) was termed the ‘GHT start value’. Measurements
taken after the ﬁrst GH dose were termed ‘during GHT values’. The
value closest to 1 year (±6months) after theﬁrst GHTdosewas deﬁned
as the ‘1-year follow-up value’. As there appeared to be increasing var-
iability with increasing IGF-I values, the analysis was performed on
log-transformed values. The pre-GHT IGF-I values were assumed to de-
pend on diagnosis, sex and age. Thiswas considered to be similar during
GHT, but with the addition of a treatment-effect dependent on diagno-
sis, sex and GH dose. The ﬁxed effects were as described above with the
addition of an assay effect. Consequently, the differences between as-
says were assumed to be multiplicative on the original scale. The ran-
dom part of the model consisted of a patient level (different baseline
values), patient treatment effect (different GHT responsiveness) and a
residual error (measurement error). All randomeffectswere considered
to be normally distributed.
Based on the multiplicative assay effects, the individual measure-
ments were scaled to a common level (based on Nichols Advantage
since this has been the most frequently used assay within the
NordiNet® IOS study period) in order to calculate adjusted IGF-I SDS
values. The adjusted values derived from the model were compared to
the unadjusted values both at GHT start and during treatment.
To evaluate the possible bias introduced by using different reference
values, IGF-SDS values were calculated for the same sample (data with
available assay information) based on two additional reference value
sets [8,14]. The Elmlinger reference values were based on the Immulite
assay, and the Bidlingmaier reference values on the IDS-iSYS IGF-I assay.
To evaluate the representativeness of the sample, the unadjusted
values with assay information were compared to the unadjusted values
of the data without assay information.
The statistical software used was SAS version 9.3.
3. Results
In the current analysis, 49 495 IGF-I measurements available from
9481 paediatric patients diagnosed with GHD, SGA or TSwere included.
Within the population for whom IGF-I data were available, 6036 had a
diagnosis of GHD; 2516 had SGA and 929 had TS. Patient age ranged
from 3 years to 18 years in all patient groups (see Supplementary
Table 1 for details of baseline demographics, clinical diagnosis, GHT
and assay information for patients in the current analysis).
For approximately 16% of IGF-I measurements, information on the
assay type/fabricant was available, with the Nichols Advantage
(Nichols Diagnostics) (27%), Mediagnost (Mediagnost GmhH) (21%),
Immunotech (Immunotech) (19%), DSL (Diagnostic Systems Labora-
tories) (13%), Biochem RIA (7%), Immunodiagnostik (5%) and
Immulite (Siemens) (7%) being the most frequently used assays
(three other assays representing 0.8% were not included in the
analysis).
Approximately 70% of the reported measurements were made on
GHD patients, 21% on SGA patients and 9% on TS patients. Themeasure-
ments were 7% pre-GHT and 93% during treatment. Out of a total of
1892 patients with available IGF-I assay information, 73.4% were mea-
sured with only one assay, 20.1% were measured with two assays and
6.5% were measured with more than two assays.
IGF-I levels and the variability of themeasurements did, as expected,
increase with age (see Supplementary Fig. 1). Mean IGF-I levels in pre-
growth hormone treated patients were estimated according to age, sex
and diagnosis (Fig. 1; see also Supplementary Table 2 and Supplementa-
ry Fig. 2 (A–E), which show estimated IGF-I levels by age group, sex and
indication, together with 95% conﬁdence intervals). Themultiplicity ad-
justment factors for the different assayswere calculated (Table 1, Fig. 2).
Fig. 2 illustrates the data for patients with a GHD diagnosis (see Supple-
mentary Fig. 3 for SGA and TS plots and similar trends). The estimated
values based on the different assays follow the same ranking within
the different diagnosis, Immunotech representing the highest levels ofIGF-I (+34%) followed by Immulite (+17%) and DSL (+18%) at almost
the same level. Nichols Advantage represents the point of reference;
Mediagnost (−9%), Biochem RIA (−14%) and Immunodiagnostik
(−17%) are represented by slightly lower IGF-I values.
In addition, multiplicity adjustment factors for different levels
of GHT doses were calculated (Table 1). A treatment dose of
30 μg/kg/day will result in a 10% increase in IGF-I level whereas a
treatment dose of 50 μg/kg/day will result in a 16% IGF-I increase.
The mean (±standard error [SE]) IGF-I SDS at GHT start and at 1-
year follow-up, and the mean change in IGF-I SDS from GHT start and
to 1-year follow-up were calculated for the patients with known
(Table 2, columns A–D) and unknown (Table 2, column E) IGF-I assay
information. The values are given for each of theﬁve subgroups (divided
by diagnosis and sex) included in this study. Table 2, column A shows
the IGF-I SDS values as they are currently calculated in NordiNet® IOS
using the Brabant reference. Patients with GHD initiate GHT with the
lowest IGF-I values (−1.7 SDS) and those with SGA start with the
highest values (−0.7 SDS). All subgroups show increases of around
2 SDS during the ﬁrst treatment year. In Table 2, column B the IGF-I
SDS values adjusted for the IGF-I assay using the multiplicity factors
from the developed model are presented alongside the difference
from Table 2, column A. The largest differences between adjusted and
unadjusted values, using the same reference, are seen for GHD after
one treatment year (−0.3 SDS). The differences in the calculated
A B
Fig. 2. Estimated pre-treatment IGF-Imean levels according to seven different assays (BiochemRIA, DSL, Immulite, Immundiagnostik, Immunotech,Mediagnost andNichols Advantage) as
a function of age, sex and diagnosis. (A) Growth hormone deﬁciency (GHD) girls and (B) GHD boys. (See also Supplementary Fig. 3 for small-for-gestational age and Turner syndrome
data.)
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from−0.1 to 0 SDS.
In Table 2, columns C and D, IGF-I SDS values based on the
Bidlingmaier and Elmlinger reference values are shown. For the
Bidlingmaier reference values, the greatest difference from Table 2, col-
umn A is seen in GHD girls at GHT start (1.1 SDS). For the calculated
change during the ﬁrst treatment year, the differences arewithin the in-
terval from −0.2 to 0.1 SDS for the Bidlingmaier reference. For the
Elmlinger reference the biggest difference is seen for SGA boys (−0.4
SDS). The calculated change values are in the interval from −0.3 to
0.1 SDS.
In Table 2, column E IGF-I SDS values for the patients without assay
information are shown. The differences to column A are in the interval
−0.4 to 0.4 SDS for the GHT start and 1-year follow-up values. For the
change from GHT start to 1-year follow-up values the differences
range from−0.2 to 0.2 SDS.
4. Discussion
The current approach when analysing NordiNet® IOS data has been
to use the age- and sex-related normative data of Brabant et al. as IGF-I
reference data, since that dataset was based on a large cross-sectional
sample of almost 4000 healthy subjects aged 1 month to 88 years,
with IGF-I assessed in six laboratories using Nichols Advantage assay
[2]. The results of our study suggest that although reported IGF-I levels
differ depending on the assays used, these differences could be
minimised by evaluating changes in IGF-I SDS values.
After adjustment for assay variability and correction for GH dose, it
was shown that IGF-I data fromNordiNet® IOS follow the expected pat-
terns for age, diagnosis and sex. The results of the mixed-effect linear
model showed a systematic difference between the IGF-I levels when
measured by different assays. Conversion of IGF-I values from one
assay to another using multiplicity factors has been described and vali-
dated previously by Krebs et al, who compared different assays for IGF-I
and also chose the Nichols Advantage as a standard against which to as-
sess the effects of GHT on IGF-I levels [3]. This difference, which we also
observed, introduces an inevitable systematic error when using the
same normative data for absolute SDS calculation.
At the start of GH therapy and 1-year follow-up we only observed
bias up to 0.3 SDS when comparing the adjusted mean values with the
unadjustedmean values using the same reference data (Table 2, columnB). When looking at the mean change in IGF-I SDS from GHT start to 1-
year follow-up, however, the bias was minimised to 0.1 SDS.
When comparing the unadjusted IGF-I SDS values using different
reference data sets we observed larger differences; however, these dif-
ferences were also minimised when evaluating the delta IGF-I SDS
values (Table 2, columns C, D). For GHD the largest absolute difference
between unadjusted changes in IGF-I SDS values was 0.1 SDS for girls
and 0.3 for boys; for SGA it was 0.1 SDS and for TS the largest difference
was 0.2.
To evaluate the representativeness of the sample, the unadjusted
values with assay information were compared to the unadjusted values
of the data without assay information (Table 2, column E). The maxi-
mum absolute difference between the unadjusted delta SDS values
was 0.2 SDS in the TS girls.
This analysis of NordiNet® IGF-I data demonstrates that there is a
systematic difference between IGF-I levels measured by different as-
says. The current data showed that modest bias was introduced by
using a single reference data set [2] for calculation of IGF-I SDS values.
Nevertheless, when analysing treatment outcomes in the NordiNet®
IOS study, it seems possible to minimise this bias using only changes
in IGF-I SDS levels (delta IGF-I SDS values) in our models. Furthermore,
analysing changes in IGF-Imeasurements (delta IGF-I SDS)was found to
be useful even if information on the type of assaywas lacking and there-
by provided an opportunity to include those values in statistical analy-
ses which would have been excluded when comparing absolute levels
(IGF and IGF-I-SDS).
The mixed-effect linear model used in the current study included
assay, diagnosis, sex, age and GHT, although numerous other parame-
ters could have been included in the model. Interpretation of IGF-I
data for NordiNet® IOS in girls over the age of 14 years and boys
over the age of 16 years is complicated by puberty. It is known that
in otherwise healthy children, after puberty there is a fall in IGF-I
levels and that during puberty there are large variations in IGF-I
levels, with increases in early puberty and decreases in later puberty
as deﬁned by Tanner stage [15]. However, in the patients in
NordiNet® IOS receiving GH therapy, puberty was not corrected for
in the model and IGF-I values in patients in the study reﬂect both en-
dogenous and exogenous GH effects on IGF-I. Numerous other factors
also impact the circulating IGF-I levels, such as ethnicity, body mass
index, thyroid hormones, cortisol, sex steroids, insulin sensitivity
and ﬁtness level [16] but, to have an approach based on core variables
Table 2
Mean IGF-I SDS at treatment start and 1-year follow-up and the mean change in IGF-I SDS from treatment start to 1-year follow-up for the patients with known IGF-I assay information.
Columns A–D show data with assay information, column E shows data without assay information. Column A shows IGF-I SDS values using the Brabant reference; column B is IGF-I SDS
values adjusted using the multiplicity factors; in columns C and D, IGF-I SDS values are based on the Bidlingmaier and Elmlinger reference values.
With assay information Without assay information
A
Brabant (unadj.)
B
Brabant (adj.)
C
Bidlingmaier (unadj.)
D
Elmlinger (unadj.)
E
Brabant (unadj.)
IGF-I SDS
Mean (SE)
IGF-I SDS
Mean (SE)
Diff to (A)
Mean (SE)
IGF-I SDS
Mean (SE)
Diff to (A)
Mean (SE)
IGF-I SDS
Mean (SE)
Diff to (A)
Mean (SE)
IGF-I SDS
Mean (SE)
Diff to (A)
Mean (SE)
Year 0 GHD Female −1.7 (0.10) −1.9 (0.10) −0.2 (0.03) −0.7 (0.09) 1.1 (0.04) −1.4 (0.13) 0.3 (0.07) −1.9 (0.06) −0.2 (0.12)
Male −1.7 (0.09) −1.9 (0.09) −0.2 (0.02) −1.2 (0.08) 0.5 (0.05) −1.8 (0.09) −0.1 (0.05) −1.8 (0.04) −0.1 (0.10)
SGA Female −0.7 (0.14) −0.9 (0.14) −0.1 (0.03) −0.1 (0.13) 0.7 (0.06) −0.7 (0.15) 0.1 (0.09) −0.7 (0.07) 0.1 (0.16)
Male −0.7 (0.13) −0.8 (0.13) 0.0 (0.03) −0.9 (0.10) −0.1 (0.08) −1.1 (0.13) −0.3 (0.09) −0.7 (0.07) 0.0 (0.15)
TS Female −1.1 (0.19) −1.1 (0.18) 0.0 (0.05) −0.1 (0.18) 1.0 (0.08) −0.8 (0.21) 0.3 (0.10) −0.9 (0.08) 0.2 (0.21)
Year 1 GHD Female 0.5 (0.10) 0.2 (0.10) −0.3 (0.04) 1.4 (0.09) 1.0 (0.03) 0.7 (0.09) 0.2 (0.05) 0.1 (0.06) −0.4 (0.12)
Male 0.3 (0.10) 0.0 (0.09) −0.3 (0.03) 0.6 (0.08) 0.3 (0.04) 0.0 (0.07) −0.3 (0.04) 0.3 (0.05) 0.0 (0.11)
SGA Female 1.0 (0.14) 0.8 (0.13) −0.2 (0.05) 1.7 (0.13) 0.7 (0.04) 1.1 (0.12) 0.1 (0.07) 0.9 (0.07) −0.1 (0.16)
Male 1.1 (0.15) 1.0 (0.15) −0.1 (0.05) 0.9 (0.12) −0.2 (0.07) 0.7 (0.11) −0.4 (0.07) 1.0 (0.07) −0.1 (0.17)
TS Female 0.9 (0.19) 0.9 (0.17) −0.1 (0.07) 1.8 (0.18) 0.9 (0.05) 1.0 (0.14) 0.1 (0.09) 1.3 (0.09) 0.4 (0.21)
Change GHD Female 2.2 (0.11) 2.1 (0.11) −0.1 (0.02) 2.1 (0.10) −0.1 (0.02) 2.1 (0.11) −0.1 (0.06) 2.0 (0.06) −0.2 (0.13)
Male 2.0 (0.09) 1.9 (0.09) −0.1 (0.02) 1.8 (0.07) −0.2 (0.02) 1.7 (0.08) −0.3 (0.05) 2.2 (0.05) 0.2 (0.10)
SGA Female 1.8 (0.16) 1.6 (0.15) −0.1 (0.03) 1.8 (0.16) 0.1 (0.02) 1.8 (0.16) 0.1 (0.06) 1.6 (0.07) −0.2 (0.18)
Male 1.8 (0.13) 1.8 (0.13) −0.1 (0.03) 1.8 (0.12) −0.1 (0.03) 1.8 (0.12) −0.1 (0.06) 1.7 (0.07) −0.1 (0.15)
TS Female 2.0 (0.19) 2.0 (0.20) 0.0 (0.03) 1.9 (0.16) −0.1 (0.04) 1.8 (0.18) −0.2 (0.09) 2.2 (0.10) 0.2 (0.21)
GHD, growth hormone deﬁciency; SDS, standard deviation score; SGA, small-for-gestational age; SE, standard error; TS, Turner syndrome.
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model.
In our previous analyses of the NordiNet® IOS outcome data we
evaluated change in IGF-I SDS after GHT initiation [11,12]. In a study
investigating gender-related differences in change from baseline
height standard deviation scores (HSDS) after 2 years of GHT, mean
delta IGF-I SDS from baseline ranged between 1.71 and 2.62 SDS
across all indications. For patients with GHD, delta IGF-I SDS was sig-
niﬁcantly greater in boys than in girls (female–male difference:
−0.27, p b 0.05). However, after adjustment for GH dose, age at base-
line and HSDS at baseline, no signiﬁcant differences in delta IGF-I SDS
for boys and girls over 2 years of treatment was found. For patients
with multiple pituitary hormone deﬁciency (MPHD) and SGA, delta
IGF-I SDS was not signiﬁcantly different between boys and girls (dif-
ference MPHD:−0.59, difference SGA:−0.34) [12].
Another study based on NordiNet® IOS compared the response to 2-
years of GHT in children with isolated growth hormone deﬁciency
(IGHD), SGA, idiopathic short stature or MPHD. The mean change in
IGF-I SDS for the total population was greater than +2.00 SDS after 1
and 2 years of GHT in all indications, except in children born SGA at 1
year. At 1 and2 years of treatment, children born SGAhad a signiﬁcantly
lower IGF-I increase than children with IGHD (+1.80 vs. +2.36 SDS,
and +2.00 vs. +2.57 SDS, respectively, p b 0.001) [11].
Non-interventional studies are characterised by certain limitations
mainly related to selection or information biases and confounding fac-
tors. For example, there may have been observations that prompted cli-
nicians to measure IGF-I levels leading to bias, or there may have been
clinic visits where IGF-I levels were not measured. Additionally, the
study may not consider the levels of non-compliance that are common
in paediatric populations. Nevertheless, our paper has sought to address
the limitation imposed by temporal trends and disparate practices and
uses of available IGF-I assays in patients registered within the
NordiNet® IOS.
The data reported and discussed herein provide useful insights into
approaches for analysing and interpreting data gathered from real-
world practice as collected by observational studies reﬂecting variable
clinical practices and methods. NordiNet® IOS is the ﬁrst observational
study to report on real-world IGF-I assay data, its analysis and interpre-
tation, and the ﬁndings reported heremay offer a framework for studies
with a similar design. The results of the analysis and modelling de-
scribed here suggest that the current approach to IGF-I data collectionand analyses from the NordiNet® IOS performed to date is founded on
sound principles. In a large cohort where information on the assay
used is often lacking, a potential bias is minimised by analysing changes
in IGF-I SDS (delta IGF-I SDS).
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